


Dolasetron

| | |
|--------------------|--|
| Cat. No.: | HY-B0750 |
| CAS No.: | 115956-12-2 |
| Molecular Formula: | C ₁₉ H ₂₀ N ₂ O ₃ |
| Molecular Weight: | 324.37 |
| Target: | 5-HT Receptor |
| Pathway: | GPCR/G Protein; Neuronal Signaling |
| Storage: | 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 300 mg/mL (924.87 mM)
* "≥" means soluble, but saturation unknown.

| | Solvent Concentration | Mass | 1 mg | 5 mg | 10 mg |
|------------------------------|--------------------------|------|-----------|------------|------------|
| | | | | | |
| Preparing Stock Solutions | 1 mM | | 3.0829 mL | 15.4145 mL | 30.8290 mL |
| | 5 mM | | 0.6166 mL | 3.0829 mL | 6.1658 mL |
| | 10 mM | | 0.3083 mL | 1.5414 mL | 3.0829 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

| | |
|---------------------------|--|
| Description | Dolasetron(MDL-73147) is a serotonin 5-HT ₃ receptor antagonist used to treat nausea and vomiting following chemotherapy. |
| IC ₅₀ & Target | 5-HT ₃ Receptor |

REFERENCES

- [1]. Faria C, et al. Outcomes Associated with 5-HT₃-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis. Am Health Drug Benefits. 2014 Jan;7(1):50-8.
- [2]. Schwartzberg L, et al. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer. 2014 Feb;22(2):469-77.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA